Here we investigate the potential clinical utility of the measurement of serum epidermal growth factor receptor 3 (i.e., ERBB3) in hepatitis C virus-infected patients with early hepatocellular carcinoma. Here, ERBB3 is linked to hepatocellular carcinoma.